ReviewJournal of thoracic disease2017
The DESolve novolimus bioresorbable Scaffold: from bench to bedside.
Review in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Dynamic stiffness enables stage-specific properties mediating functional endothelialization on vascular implants.Science advances · 2026Article
- Bioresorbable Scaffolds: Ready for a Rematch?Current cardiology reports · 2026Review
- Integrating stent design and microstructural characterization to improve clinical outcomes of bioresorbable stents.Materials & design · 2025Article
- Mechanically robust neuroprotective stent by sequential Mg ions release for ischemic stroke therapy.Nature communications · 2025Article
- Advances in Fabrication Technologies for the Development of Next-Generation Cardiovascular Stents.Journal of functional biomaterials · 2023Review
- Polylactide Perspectives in Biomedicine: From Novel Synthesis to the Application Performance.Pharmaceutics · 2022Review
- Long-term results of long segment coronary artery lesions overlapped with novolimus-eluting DESolve scaffold: Disappointment or futuristic?Anatolian journal of cardiology · 2021Article
- The Development of Design and Manufacture Techniques for Bioresorbable Coronary Artery Stents.Micromachines · 2021Review
- Bioresorbable Scaffolds in Percutaneous Coronary Intervention: Facing Old Problems, Raising New Hopes.Current cardiology reports · 2021Review
- Bioresorbable Scaffolds: Contemporary Status and Future Directions.Frontiers in cardiovascular medicine · 2020Review
- Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?Journal of clinical medicine · 2019Review
- Biocompatible Polymer Materials with Antimicrobial Properties for Preparation of Stents.Nanomaterials (Basel, Switzerland) · 2019Review
- Revolutionizing Cardiovascular Frontiers: A Dive Into Cutting-Edge Innovations in Coronary Stent Technology.Cardiology in reviewReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.